Krystal Biotech Inc represents values of innovation, dedication, and excellence in the field of biotechnology. The company is committed to developing and delivering advanced gene therapies to treat rare skin diseases. With a vision to transform lives, Krystal Biotech focuses on providing effective and safe solutions that address unmet medical needs. Their corporate philosophy revolves around promoting patient-centric care, scientific rigor, and ethical practices. By leveraging cutting-edge technology and scientific expertise, Krystal Biotech strives to enhance the quality of life for individuals affected by genetic skin disorders.

Krystal Biotech Inc is primarily present in the United States.

Krystal Biotech Inc has achieved several significant milestones. One of the notable achievements includes the successful completion of the phase 2 clinical trial for their gene therapy product, known as KB103. This product aims to treat a rare skin disorder called dystrophic epidermolysis bullosa (DEB). Additionally, the company has also achieved positive results in pre-clinical trials for other gene therapy candidates, showcasing their potential to address various genetic disorders. Krystal Biotech Inc has received several grants and awards for their innovative research and development efforts. These achievements highlight the promising growth and potential of Krystal Biotech Inc in the field of gene therapy.

Krystal Biotech Inc, headquartered in Pittsburgh, Pennsylvania, is a clinical-stage gene therapy company focused on developing and commercializing transformative treatments for patients suffering from rare genetic diseases. Founded in 2015, Krystal Biotech is driven by a mission to deliver potentially curative therapies that address the unmet medical needs of patients worldwide. Leveraging its proprietary Skin TARgeted Delivery platform, the company aims to develop innovative gene therapies for dermatological conditions, starting with its lead product candidate, KB105. Through strategic collaborations, Krystal Biotech strives to revolutionize the treatment landscape by advancing gene therapies to provide hope for patients and their families.

The main competitors of Krystal Biotech Inc in the market include companies such as Regenxbio Inc, bluebird bio Inc, and Sangamo Therapeutics Inc. These companies have a similar focus on gene therapy and are actively engaged in the development and commercialization of innovative treatments for genetic diseases. Krystal Biotech Inc competes with these companies in terms of research, development, and market adoption of gene therapy products.

Krystal Biotech Inc is primarily active in the biotechnology and pharmaceutical industries.

Krystal Biotech Inc is a biopharmaceutical company specializing in gene therapies. Their business model focuses on developing and commercializing innovative treatments to address severe dermatological diseases. By harnessing the power of gene therapy, Krystal Biotech aims to provide targeted and sustainable solutions for patients, offering potential long-term benefits. With a strong emphasis on cutting-edge research and development, they strive to revolutionize the treatment landscape by creating novel therapies that address unmet medical needs. Krystal Biotech Inc's business model is driven by a commitment to scientific excellence and a passion for improving the lives of patients suffering from dermatological conditions.

Pašreizējais KGV Krystal Biotech nevar tikt aprēķināts.

KUV šobrīd Krystal Biotech nevar aprēķināt.

AlleAktien kvalitātes vērtējums Krystal Biotech ir 2/10.

gaidāmā Krystal Biotech apgrozījums ir 467,38 milj. USD.

gaidāmā Krystal Biotech peļņa ir 209,38 milj. USD.

Krystal Biotech Inc is a biotechnology company focused on developing gene therapy products for rare dermatology and genetic diseases. The company aims to develop innovative therapies that improve the lives of patients with rare diseases. The business model is based on the development and commercialization of gene therapy products. Krystal Biotech uses a proprietary gene therapy platform called HSV-1 vector to develop therapies for serious and rare dermatological conditions such as Epidermolysis bullosa, Netherton syndrome, and Heidelberg syndrome. The company's gene therapy products utilize the HSV-1 vector's ability to introduce DNA into rapidly dividing cells, such as skin cells, to replace the defective gene causing the disease and restore normal functioning of the affected cells. Krystal Biotech focuses on developing gene therapies for severe and rare diseases where effective treatments are often lacking. The company has several gene therapy products in development, including KB103 for the treatment of Epidermolysis bullosa, KB105 for the treatment of Netherton syndrome, and KB104 for the treatment of Heidelberg syndrome. KB103 is currently in phases 1 and 2 of clinical development and has the potential to become the first approved gene therapy product for treating Epidermolysis bullosa. Krystal Biotech also places a strong emphasis on collaboration with other companies and stakeholders in the biotechnology industry. The company has entered into a collaboration agreement with the international pharmaceutical company Bayer to develop a gene therapy platform for the treatment of serious eye diseases. In summary, Krystal Biotech's business model is based on the development and commercialization of gene therapy products for rare dermatological and genetic diseases. The company aims to improve the lives of patients with severe and rare diseases and seeks partnerships and alliances with other biotechnology companies and stakeholders in the industry to achieve this goal.

Krystal Biotech izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Krystal Biotech vai uzņēmums nedod dividendes.

Krystal Biotech ISIN ir US5011471027.

Krystal Biotech WKN ir A2JH2F.

Krystal Biotech simbols ir KRYS.

Pēdējo 12 mēnešu laikā Krystal Biotech maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Krystal Biotech plāno maksāt dividendes 0 USD apmērā.

Krystal Biotech pašreizējā dividendu rentabilitāte ir .

Krystal Biotech maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Krystal Biotech pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Krystal Biotech tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Krystal Biotech apmērā 0 USD, kas tika izmaksāta 17.04.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.04.2025..

Pēdējās dividendes izmaksa notika 17.04.2025..

Gadā 2024, Krystal Biotech izmaksāja 0 USD dividendes.

Krystal Biotech dividendes tiek izmaksātas USD.